← The Wire
RLMDNasdaq
RELMADA THERAPEUTICS, INC.
Pharmaceutical Preparations · NV · CIK 1553643
Relmada Therapeutics develops novel drug formulations for bladder cancer and neurological disorders
$698M
Market cap
$6.98
Last close
+4.3%
1D
+1.3%
5D
2.3M
Volume
Price · last 39 sessions-5.8%
May 4L $5.72 · H $7.86Jun 29
272
Total filings
May 28, 2026
Last filing
12/31
Fiscal year end
424B5PROSPECTUS SUPPLEMENTJan 30, 2026424B5PROSPECTUS SUPPLEMENTNov 5, 2025424B5PROSPECTUS SUPPLEMENTApr 28, 2025424B5PROSPECTUS SUPPLEMENTDec 10, 2021424B5PROSPECTUS SUPPLEMENTDec 8, 2021424B5PROSPECTUS SUPPLEMENTMay 15, 2020424B5PROSPECTUS SUPPLEMENTDec 5, 2019424B5PROSPECTUS SUPPLEMENTDec 3, 2019
Insider Activity
◆ Cluster Buy · 4 insidersIn the 90 days to Dec 15, 2025: 4 insiders bought $2.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 15, 2025 | Traversa SergioChief Executive Officer | Buy | 27,500 | $4.12 | $113K |
| Dec 15, 2025 | Shenouda MagedChief Financial Officer | Buy | 11,665 | $4.12 | $48K |
| Nov 5, 2025 | Shenouda MagedChief Financial Officer | Buy | 500,000 | $2.20 | $1.1M |
| Nov 5, 2025 | Traversa SergioChief Executive Officer | Buy | 272,500 | $2.20 | $600K |
| Nov 5, 2025 | Ence ChuckCAO and COO | Buy | 136,000 | $2.20 | $299K |
| Nov 5, 2025 | Kelly Paul EdwardChief Operating Officer | Buy | 90,000 | $2.20 | $198K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance